Compare CSX Corporation (CSX) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Gilead Sciences, Inc. — how do they compare? CSX Corporation trades at $47.34 (market cap $86.70B), while Gilead Sciences, Inc. trades at $147.1 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× CSX Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Gilead Sciences, Inc. for 111 Days on average.
| CSX | GILD | |
|---|---|---|
Market Cap | $86.70B | $182.09B |
Volume | 6,811,485 | 4,960,247 |
Sector | Industrials | Health |
52-Week High | $53.21 | $155.80 |
52-Week Low | $33.68 | $116.74 |
Typical Hold Time | 55 Days | 111 Days |
Enterprise Value | $104.66B | $205.15B |
Dividend Yield | 1.2% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.34, down 0.34% today, with a bearish technical signal from moving averages. Recent earnings show mixed quarterly results, beating in Q1 and Q2 2026 but missing in Q4 2025. Revenue has declined from $14.9B in 2022 to $14.1B in 2025, though net income margin remains strong at 22.21%. Analyst consensus is bullish with a $51.00 price target, supported by institutional buying and positive news on dividend sustainability.
The outlook for CSX hinges on reversing revenue declines and executing on projected 2026 growth. Risks include competitive pressures and economic sensitivity, but strong profitability and analyst support offer upside. Investors should weigh valuation premiums against operational resilience in the freight sector.
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
